Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

26 May 2023  Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy DUO-E is the first global Phase III trial of immunotherapy plusPARP inhibition to demonstrate clinical benefit in this setting Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically

The subscription period in Bioservo’s rights issue begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION.Today, May 26, 2023, the subscription period in Bioservo Technologies AB’s (“Bioservo” or the “Company”) rights issue of approximately MSEK 37 begins, which was resolved by the board of directors of Bioservo on May 15, 2023, based on the authorisation of the

HC Andersen Capital Events 26/5: Meet the management in Tryg, Qlife and GomSpace

HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.How does Tryg work with innovation?Get updated on how the insurance company Tryg works with innovation when we host an event about this specific subject.From Tryg we have COO and member of the group management Lars Bonde, who for many years has been responsible for IT and Nordic Innovation - Lars will update us on how Tryg works with new services and products. The event will be held in Danish.Disclaimer: HC Andersen Capital receives

DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby inform the market and its investors that it is currently engaged in advanced discussions with a new investor regarding an additional DKK 12 million to supplement the outcome of TO 2's. The agreement is based on a loan agreement with conversion options and initially has a scope of DKK 12 million, which can potentially increase to a total of DKK 18 million. The agreement will be subject to an approval on an Extra General Meeting.

Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023

Opening remarks   During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H.   Hamlet Pharma has also successfully completed its Horizon 2020 project, receiving the last part of the grant, which means full funding. The European Commission commended Hamlet Pharma for its progress and stated that the project had fully

Awarding the Munin jacket

Aker BP (OSE:AKRBP, OTCQX:AKRBF) has awarded Heerema Vlissingen a contract for procurement and construction for the Munin jacket in the Yggdrasil area.   “This is an important contract for the Yggdrasil development. With this award we have placed all major fixed facilities contracts in the Yggdrasil area, and we are in line with our execution plan,” states Project Director Peter Kupka for fixed facilities deliveries in Yggdrasil.   “Heerema Fabrication Group Vlissingen is an experienced international contractor with a solid track record. I am very pleased that they will

Genetic Analysis AS: Mandatory notification of trade – Primary Insiders

OSLO, NORWAY – 26 May 2023: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS yesterday bought 33.250 GEAN shares at an average price of 1,71 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 225.290 shares and 26.909 tradable subscription rights GEAN T02.

Invitation to Huddlestock’s Q1 2023 presentation & capital markets day on 1 June 2023

Bricknode has the pleasure of extending an invite to investors, analysts and media to join Huddlestock’s Q1 2023 presentation & capital markets day on 1 June 2023, 12:00 – 14:00 CEST. The event will be hosted by Huddlestock’s CEO John E. Skajem, together with members of the executive management team.Bricknode completed the sale of all its operational assets to Huddlestock on 4 April, as previously announced. The capital markets day will include discussion about Huddlestock’s first quarter 2023 financial results, followed by an update on the company’s strategy and growth opportunities in

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Oslo, 26 May 2023 – Following the closing of the acceptance period in the previously announced public offer, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, will become the owner of 96.33 per cent of the share capital and votes and 93.16 per cent of the series TO 1 warrants ("Warrants") in Sensidose Aktiebolag ("Sensidose).This is an important milestone in Navamedic’s plan to acquire all outstanding shares and include Sensidose’s product offering in its well proven and highly scalable market access platform for

Greenfood’s Interim report first quarter 2023

The first quarter of the year represents a strong start to 2023. Group sales are up 20.7% and Adjusted EBITDA almost doubled.INTERIM OVERVIEW 1 JANUARY - 31 MARCH · Net sales for the period totalled SEK 1,450.1 million (1,201.0) an increase of 20.7%. Out of the increase of SEK 249.1 million, SEK 112.4 million increase is generated at Picadeli, mainly due to a larger established base of buying stores. · Adjusted EBITDA was with SEK 42.4 million (22.3) significantly better than the first quarter 2022. The main driver is Picadeli with a SEK 18.2 million increase, caused by increased

Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to legislation, restrictions and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders and Warrant Holders (as defined below) not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders and Warrant Holders should refer to the offer

Orders of NOK 8.2m received to date, representing annual recurring sales potential of approx NOK 50 million

Oslo, 26 May 2023 – Observe Medical ASA (the "Company" or "Observe Medical") has received initial orders from distributors for delivery of UnoMeter™ products and is expecting to ship the first units to customers in June. The total value of these initial orders is NOK 8.2 million. The distributors that have signed the orders have historically had annual repetitive purchases of around NOK 50 million. Dialogues with these and other distributors continue to advance, and with products expected to be on the market relatively soon, Observe Medical is expecting additional orders to be confirmed.

GomSpace Q1 2023 Report and Status Update

GomSpace releases its Q1 2023, and the CEO outlines plans for bringing the company to profitabilityFIRST QUARTER OF 2023 · Order intake was T.SEK 33,454 (41,497) · Net revenues of T.SEK 78,150 are in line with Q1 2022 (78,365) · Gross margin this quarter is positive 12%, compared to negative 26% for full year 2022 · Operating profit (EBIT) decreased to negative T.SEK 14,078 (4,166) · Earnings per share were negative SEK 0.24 (SEK 0.06) Main events: · Changed model for market guidance from Revenue and EBIT, to focus on Free Cashflow. The guidance for a free cash flow

Betolar's solution supports Indian architects, real estate developers and contractors in the green transition

Friday, 26 May 2023, Ahmedabad, India. Betolar's Indian partner, Vyara Tiles, will launch locally produced low-carbon concrete products with the Geoprime® solution at the ACE Reflect event in Ahmedabad, India, on May 26-27, 2023, targeting architects, designers, and property developers. "In our environmentally friendly construction products developed with Vyara Tiles, cement has been completely replaced with circular economy materials, drastically reducing their CO2 emissions. The green transition requires a change in thinking throughout the value chain, from ordering to construction,"

ShaMaran Corporate Update

VANCOUVER, BC, May 25, 2023 /CNW/ - ShaMaran Petroleum Corp. (TSX Venture and Nasdaq First North: SNM) (“ShaMaran Petroleum” or the “Company”) has granted incentive stock options to certain officers, employees and other eligible persons of the Company to acquire 29,400,000 shares of the Company at an exercise price of CAD$0.063 per share.  The options are exercisable, subject to vesting provisions, over a period of five years.  ShaMaran has also granted 19,750,000 restricted share units at a price of CAD$0.063 to certain officers, employees and other eligible persons of the Company.  The

CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023

CHOSA Oncology AB today publishes results from the prospective phase 2 study of LiPlaCis® (a liposomal formulation of cisplatin) in previously heavily treated patients with metastatic breast cancer as the abstract is being released on the ASCO website on May 25, 2023, at 5:00 PM (ET) / 23:00 CET (please see a link to ASCO’s website below). This patient group was tested using the diagnostic tool Drug Response Prediction (DRP®), which is a 205 mRNA biomarker signature, that assesses whether the patient is likely to respond to cisplatin treatment - or not. The results show that patients who get

Africa Oil Announces Annual Meeting Voting Results

VANCOUVER, BC, May 25, 2023 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) is pleased to report the voting results from the Company’s annual general meeting of shareholders held today in Vancouver, British Columbia.   A total of 176,009,443 common shares were voted at the meeting, representing 38.07% of the votes attached to all the outstanding common shares of the Company. Shareholders voted in favour of all items of business as follows:   +---------------------------------------------+------+----------+|Election of Directors

OXE MARINE AB (PUBL) APPOINTS PAUL FRICK AS NEW CEO

The board of directors of OXE Marine AB (publ) (the “Company”) has resolved to appoint Paul Frick as CEO effectively from Monday 29[th] May, following the resignation of Anders Berg who will stay on for a smooth transition period. “We are very pleased with the appointment of Paul Frick as the new CEO of OXE Marine. In his role as CFO he has done a fantastic job in managing the company’s finances and played a vital part in improving the company’s financial position, as well as engaging with the company’s shareholders and investor community. Paul has also been actively involved in

Nordea Bank Abp: Repurchase of own shares on 25.05.2023

Nordea Bank AbpStock exchange release – Changes in company’s own shares25.05.2023 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 25.05.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |163,206|9.42 |1,536,910.

Bulletin from the Annual General Meeting of Implantica AG

Today, May 25, 2023, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Ruggel, Liechtenstein. The general meeting resolved to adopt all of the board of directors’ resolution proposals. A summary of the resolutions adopted at the general meeting is set out below.The general meeting adopted the annual report 2022 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG for the financial year 2022, acknowledging the reports of the auditors. The general meeting resolved to carry forward the net loss for the financial

Bulletin from Sivers Semiconductors AB (publ)’s Annual General Meeting on 25 May 2023

The Annual General Meeting in Sivers Semiconductors AB (publ) (the “Company”) has been held on 25 May 2023 and in particular the following decisions were resolved.Adoption of the annual report and the auditor’s report  The Annual General Meeting resolved to approve the profit and loss statement and the balance sheet regarding the parent Company and the Group, appropriation of the profit in accordance with the Board of Directors proposal and not to distribute any dividends for the financial year 2022, as well as to discharge the CEO and Board members from liability. Election of Board

Bulletin from the Annual General Meeting 2023

The Annual General Meeting 2023 of RaySearch Laboratories AB (publ) was held on May 25, 2023 in Stockholm, Sweden. The following resoulutions were adopted.It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren and Hans Wigzell as Board members of the company and to re-elect Hans Wigzell as Chairman of the Board. The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from liability. It was resolved that the accumulated profit, amounting to SEK 126,858,312 be brought forward and

Notification of Major Holdings in Catena Media plc

Catena Media plc (the "Company") hereby announces that it has on 23 May received a notification from Conifer Management, LLC, with registered office in New York, USA. The notification is with regards to a disposal of shares and voting rights in the Company (the "Notification") made by Conifer Management, LLC. The Notification indicates that Conifer Management, LLC, as of 17 May 2023, holds 4.96% of the shares and voting rights in the Company. The entire notification is available at the Company's website on the following link: https://www.catenamedia.com/corporate-governance/major-

Sivers Semiconductors obtain financing of SEK 75 million, of which a convertible loan of SEK 25 million

Sivers Semiconductors AB (the "Company") has, according to previous communication in connection with the directed new issue in April 2023, now entered into a loan agreement with Formue Nord for financing up to SEK 75 million, of which SEK 25 million is a convertible loan at a fixed conversion rate of 9.61 SEK corresponding to a dilution effect of approximately 1.1%. The company has also received a credit decision from a commercial bank for an additional SEK 25 million and is negotiating final loan agreements. With the new loan financing of a total of SEK 100 million, the Company will improve

There are no items matching the current filter
There are no more items matching the current filter
Back to top